---
title: CDMO Daily News — June 6, 2026
slug: daily-news-2026-06-06-cdmo
site: cdmo
post_kind: news
byline: BioBM
last_updated: 2026-06-06T20:56:20.513Z
---

* **Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1** — The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.
  - DURHAM, N.C., June 5, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit detection organization powered and funded by the...
  *Operational Impact:* This geographic footprint move can alter CDMO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions.
  *Source:* [PR Newswire pharma category RSS](https://www.prnewswire.com/news-releases/grifols-supports-alphadetect-to-accelerate-detection-of-alpha-1-302793071.html)
* **Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury** — Needle-Delivered Electrode Enables Outpatient Placement and At-Home Stimulation for Spinal Cord Injury Patients With Neurogenic Bladder CLEVELAND and HOUSTON, June 5, 2026 /PRNewswire/ -- Neuronoff, Inc., a clinical-stage neuromodulation company, today announced the first patient implant...
  - Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury — outsourcing teams should verify scope against the primary source.
  *Operational Impact:* This capacity & infrastructure move can alter CDMO vendor risk for comparable outsourcing scopes—confirm whether active partners still meet timeline, compliance, and site-level assumptions.
  *Source:* [PR Newswire pharma category RSS](https://www.prnewswire.com/news-releases/neuronoff-implants-first-patient-in-dod-funded-trial-of-injectrode-for-neurogenic-bladder-in-spinal-cord-injury-302792220.html)
* **[WuXi Biologics](/companies/wuxibiologics) Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility** — SINGAPORE, June 4, 2026 /PRNewswire/ -- [WuXi Biologics](/companies/wuxibiologics) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub).
  - Once operational,...
  *Operational Impact:* [WuXi Biologics](/companies/wuxibiologics)'s capacity & infrastructure signal may change which CDMO partners are credible for overlapping programs—validate capacity claims, audit history, and geographic coverage before adjusting shortlists.
  *Source:* [PR Newswire pharma category RSS](https://www.prnewswire.com/news-releases/wuxi-biologics-singapore-crdmo-hub-completes-modular-topping-out-of-drug-product-facility-302792225.html)

---
How this was written: [Transparency methodology](/transparency)

> Some claims require additional source verification.

Source: https://cdmo.directory/posts/daily-news-2026-06-06-cdmo